Juvenile idiopathic arthritis

@article{Ravelli2007JuvenileIA,
  title={Juvenile idiopathic arthritis},
  author={Angelo Ravelli and Alberto Martini},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={767-778}
}
Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years of age. This term encompasses several disease categories, each of which has distinct methods of presentation, clinical signs, and symptoms, and, in some cases, genetic background. The cause of disease is still poorly understood but seems to be related to both genetic and environmental factors, which result in the heterogeneity of the illness… Expand

Paper Mentions

Observational Clinical Trial
BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common chronic paediatric rheumatic disease (PRD) and an important cause of short and long-term disability. Although… Expand
ConditionsJuvenile Idiopathic Arthritis
Observational Clinical Trial
The purpose of this study is to determine the frequency of chronic pain in adolescent with juvenile idiopathic arthritis, especially when the disease is inactive or with minimal… Expand
ConditionsJuvenile Idiopathic Arthritis
InterventionBehavioral
Juvenile idiopathic arthritis
TLDR
Most patients with JIA do not achieve a remission and require long-term treatment, however, the use of new therapies such as methotrexate and the biologic agents has improved the outcome of JIA. Expand
Arthritis 3 Juvenile idiopathic arthritis
TLDR
New developments in genetics, immunology, and imaging are instrumental to better define, classify, and treat patients with juvenile idiopathic arthritis. Expand
Juvenile idiopathic arthritis: an update
TLDR
In the present review, the different classifications, clinical features of different categories of JIA and recent advances in the management are discussed. Expand
Diagnosing juvenile idiopathic arthritis
TLDR
The diagnosis of JIA is predominantly clinical and this review outlines the clinical features of the condition together with an approach to differential diagnosis, and the role of the limited laboratory testing is reviewed, along with recent advances in imaging which can aid diagnosis. Expand
Juvenile idiopathic arthritis - an update on pharmacotherapy.
  • P. Kahn
  • Medicine
  • Bulletin of the NYU hospital for joint diseases
  • 2011
TLDR
The clinical features of JIA are outlined as well as the latest updates in current and future pharmacotherapy to better tailor therapy for patients. Expand
Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches
TLDR
An overview of advances in understanding of JIA pathogenesis focusing on aetiology, histopathology, immunological changes associated with disease activity, and best treatment options is provided. Expand
Is Still's Disease an Autoinflammatory Syndrome?
TLDR
It seems evident that sJIA is an autoinflammatory disease related to abnormality in innate immune system, and the new insights on the pathogenesis have dramatically changed the approach to treatment, with the development of targeted treatments more effective and safer than earlier medications. Expand
Unraveling the Phenotypic Variability of Juvenile Idiopathic Arthritis across Races or Geographic Areas — Key to Understanding Etiology and Genetic Factors?
TLDR
There is strong evidence for a genetic predisposition to JIA, and the importance of genetic determinants has been demonstrated by instances of familial aggregation of JIA and by the monozygotic twin concordance rate of 25%–40%. Expand
Juvenile idiopathic arthritis.
TLDR
In the near future, it is hoped that genetic testing will allow earlier diagnosis of JIA as well as help predict the disease course of children who have JIA. Expand
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis
TLDR
In the pivotal trials for IV and SC abatacept, either with or without MTX, both formulations demonstrated clinical efficacy, with a high proportion of patients achieving stringent clinical responses, as well as improvements in patient-reported outcomes and a favorable safety profile, particularly with regard to infections. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 193 REFERENCES
New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment.
TLDR
Current knowledge of pathophysiology and experiences in the treatment of SJIA, including application of recombinant anti-IL-1 receptor antagonist or anti- IL-6 receptor antibodies in patients resistant to conventional anti-inflammatory treatment are summarized. Expand
Toward an understanding of the long-term outcome of juvenile idiopathic arthritis.
  • A. Ravelli
  • Medicine
  • Clinical and experimental rheumatology
  • 2004
TLDR
By reviewing the surveys that have analyzed the outcome of JIA in term of clinical remission, physical disability, and radiographic damage, the clinical questions that are most relevant in this area of study are addressed. Expand
Current treatment of juvenile rheumatoid arthritis.
TLDR
Randomized, placebo-controlled, clinical trials in patients with JRA are few, but one such trial with the tumor necrosis factor inhibitor etanercept shows that this drug is effective and well-tolerated. Expand
Juvenile chronic arthritis.
TLDR
Juvenile Chronic Arthritis is a relatively uncommon childhood disease, with the commonest mode of onset being pauci-articular with less than five joints in the first 3 to 6 months. Expand
Current management of juvenile idiopathic arthritis.
  • C. Wallace
  • Medicine
  • Best practice & research. Clinical rheumatology
  • 2006
TLDR
This chapter will discuss the current approaches to medical management of JIA and the medications currently available for use. Expand
Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease.
TLDR
The results support the hypothesis that patients with similar characteristics are currently classified into different JIA categories and the value of ANA positivity as a possible modifier of the current classification system deserves consideration. Expand
Early predictors of outcome in juvenile idiopathic arthritis.
TLDR
In summary, greater severity/extension of arthritis at onset, symmetric disease, precocious hip/wrist involvement, the presence of rheumatoid factor, and prolonged active disease were the best predictors of a poor outcome. Expand
Patients with juvenile psoriatic arthritis comprise two distinct populations.
TLDR
It is suggested that the presence of dactylitis, rather than age, has the greatest capacity to predict essential features of the clinical phenotype, and future studies should avoid the assumption that PsA in childhood constitutes a single etiologic entity. Expand
The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis.
TLDR
The early presence of ankle and/or wrist disease, symmetric joint involvement, and an elevated ESR in a child with oligo-JRA indicates the likelihood of disease progression. Expand
Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.
TLDR
The disease course in systemic JIA can be characterized as monophasic, polycyclic, or persistent using a definition of remission requiring 3 months of inactive disease while not receiving any therapy. Expand
...
1
2
3
4
5
...